Haleon (HLN) to Release Earnings on Thursday

Haleon (NYSE:HLN) will be releasing its earnings data before the market opens on Thursday, October 31st. Analysts expect Haleon to post earnings of $0.11 per share for the quarter.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the prior year, the company earned $0.08 EPS. On average, analysts expect Haleon to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Haleon Price Performance

Shares of NYSE:HLN traded down $0.05 during trading on Tuesday, reaching $9.93. The company had a trading volume of 779,057 shares, compared to its average volume of 5,149,451. Haleon has a twelve month low of $7.70 and a twelve month high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $45.34 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 2.90 and a beta of 0.26. The firm’s fifty day moving average is $10.24 and its 200 day moving average is $9.22.

Haleon Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s payout ratio is currently 33.33%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HLN. Morgan Stanley raised their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Berenberg Bank started coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.